Here is a recently published LDN report on PubMed from a Pennsylvania State University study:
http://www.ncbi.nlm.nih.gov/pubmed/21256121
Admittedly, the study was conducted on the EAE mouse model, but the conclusions are very encouraging and relate to treatment with either OGF or LDN (which produces high endogenous OGF levels):
1. Halted EAE disease progression
2. Reversed neurological deficits, and
3. Prevented onset of dysfunction across considerable span of time.
This is very encouraging news to those of us who use LDN.
I only use 2.0mg LDN nightly right now because of bladder related spasticity problems, but hope to work up to 4.5mg nightly over time. This article encourages me to stick-it-out.
I haven't seen this reported elsewhere, and wanted to share.
http://www.ncbi.nlm.nih.gov/pubmed/21256121
Admittedly, the study was conducted on the EAE mouse model, but the conclusions are very encouraging and relate to treatment with either OGF or LDN (which produces high endogenous OGF levels):
1. Halted EAE disease progression
2. Reversed neurological deficits, and
3. Prevented onset of dysfunction across considerable span of time.
This is very encouraging news to those of us who use LDN.
I only use 2.0mg LDN nightly right now because of bladder related spasticity problems, but hope to work up to 4.5mg nightly over time. This article encourages me to stick-it-out.
I haven't seen this reported elsewhere, and wanted to share.
Comment